Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Operating Margin (2016 - 2025)

Historic Operating Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 7160.0%.

  • Northwest Biotherapeutics' Operating Margin fell 30140600.0% to 7160.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 6927.32%, marking a year-over-year decrease of 29704900.0%. This contributed to the annual value of 4812.45% for FY2024, which is 19393600.0% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Operating Margin is 7160.0%, which was down 30140600.0% from 11281.68% recorded in Q2 2025.
  • Northwest Biotherapeutics' Operating Margin's 5-year high stood at 1473.18% during Q1 2023, with a 5-year trough of 11281.68% in Q2 2025.
  • Moreover, its 5-year median value for Operating Margin was 4284.6% (2022), whereas its average is 5075.34%.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Operating Margin soared by 2000000000bps in 2021, and later tumbled by -78573700bps in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Operating Margin (Quarter) stood at 2871.14% in 2021, then dropped by -6bps to 3044.89% in 2022, then fell by -12bps to 3402.7% in 2023, then plummeted by -135bps to 8008.23% in 2024, then increased by 11bps to 7160.0% in 2025.
  • Its last three reported values are 7160.0% in Q3 2025, 11281.68% for Q2 2025, and 4616.27% during Q1 2025.